Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in Mice

@article{Cluny2010Naphthalen1yl4pentyloxynaphthalen1yl,
  title={Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in Mice},
  author={Nina L. Cluny and Catherine M. Keenan and Marnie Duncan and Alyson J. Fox and Beat Lutz and Keith A. Sharkey},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2010},
  volume={334},
  pages={973 - 980}
}
  • N. Cluny, C. Keenan, K. Sharkey
  • Published 1 September 2010
  • Biology, Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
The endocannabinoid system is involved in the regulation of gastrointestinal (GI) motility and inflammation. Using the peripherally restricted cannabinoid (CB)1/CB2 receptor agonist naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), we investigated the role of peripheral cannabinoid receptors in the regulation of GI motility and the development of colitis in mice. The actions of SAB378 on whole gut transit, upper GI transit, colonic propulsion, and locomotor activity were… 

Figures from this paper

Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial.
TLDR
Cannabidiol and palmitoylethanolamide reduce permeability in the human colon and have implications in disorders associated with increased gut permeability, such as inflammatory bowel disease.
Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors
TLDR
This is the first evidence that central and peripheral CB receptors are responsible for the protective and therapeutic action of cannabinoids in mouse models of colitis.
Title Multitarget Fatty acid amide hydrolase / cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage Permalink
TLDR
Unlike NSAIDs, ARN2508 causes no gastric damage and indeed protects the GI from NSAID-induced damage through a mechanism that requires FAAH inhibition, andMultitarget FAAH/Cox blockade may provide a transformative approach to IBD and other pathologies in which FAAHandCox are overactive.
The Role of the Endocannabinoid System in the Brain-Gut Axis.
TLDR
The mechanisms by which the ECS links stress and visceral pain are reviewed, including how transcription of CNR1 is modified through epigenetic processes under conditions of chronic stress and how these processes might link stress with abdominal pain.
Endocannabinoids in the gastrointestinal tract.
TLDR
The role of the endocannabinoid system in gut homeostasis and in the pathogenesis of intestinal disorders associated with intestinal motility, inflammation, and cancer are focused on.
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation
TLDR
Experimental data suggest that the endocannabinoid system represents a promising target in the treatment of inflammatory bowel diseases, and this assumption is also confirmed by preliminary clinical studies.
Cannabinoids as potential new therapeutics of gastrointestinal motility and inflammatory disorders
TLDR
Two studies show that cannabinoid-mediated inhibition of guinea-pig ileum contractions is not mediated through the CB1, CB2, CBe or GPR55 receptor, and the approach of attaching a dendrimer to JWH007 to prevent central nervous system penetration does not appear to be a feasible approach.
The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of CNS activity with repeated dosing
TLDR
Significant caution is warranted regarding therapeutic use of CB-13 with the goal of avoiding CNS side effects, but the clear analgesic effect of acute peripheral CB1 receptor activation suggests that peripherally restricted cannabinoids are a viable target for novel analgesic development.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
TLDR
A new class of cannabinoid ligands was rationally designed from known aminoalkylindole agonists and showed good binding and functional activities at human CB1 and CB2 receptors, which led to the discovery of a novel CB1/CB2 dual agonist, naphthalen-1-yl-(4-pentyloxynaphthalanone), which displays good oral bioavailability, potent antihyperalgesic activity in animal models, and limited brain penetration.
Cannabinoid modulation of intestinal propulsion in mice.
Endocannabinoids as physiological regulators of colonic propulsion in mice.
TLDR
Endocannabinoids acting on myenteric CB1 receptors tonically inhibit colonic propulsion in mice, and high amounts of 2-arachidonylglycerol and particularly anandamide were found in the colon, together with a high activity of an andamide amidohydrolase.
The endocannabinoid system and the molecular basis of paralytic ileus in mice
  • N. Mascolo, A. Izzo, V. Marzo
  • Biology, Medicine
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2002
TLDR
The intestinal hypomotility typical of paralytic ileus is due, at least in part, to the enhancement of anandamide levels and CB1 expression during this condition, and that selective, nonpsychotropic CB1 receptor antagonists could represent new drugs to treat this disorder.
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis
TLDR
The show that activation of the CB2 receptor protects against experimental colitis in mice suggests a role for this receptor in normally limiting the development of colitis, and support the idea that theCB2 receptor may be a possible novel therapeutic target in inflammatory bowel disease.
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.
Six novel aminoalkylindole analogs, related structurally to the dual cyclooxygenase inhibitor and nonopioid analgesic pravadoline, were evaluated in the mouse to determine whether their
The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models.
Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation
TLDR
It is concluded that inflammation of the gut increases the potency of cannabinoid agonists possibly by ‘up‐regulating’ CB1 receptor expression; in addition, endocannabinoids, whose turnover is increased in inflamed gut, might tonically inhibit intestinal motility.
...
1
2
3
4
5
...